IGM Biosciences, Inc. (IGMS)
NASDAQ: IGMS · Real-Time Price · USD
6.90
-0.15 (-2.13%)
Dec 20, 2024, 4:00 PM EST - Market closed
IGM Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Cash & Equivalents | 42.88 | 112.52 | 121.23 | 133.33 | 241.08 | 35.89 | Upgrade
|
| Short-Term Investments | 175.91 | 225.16 | 305.93 | 96.21 | 125.19 | 188.74 | Upgrade
|
| Cash & Short-Term Investments | 218.79 | 337.68 | 427.16 | 229.54 | 366.27 | 224.63 | Upgrade
|
| Cash Growth | -43.46% | -20.95% | 86.09% | -37.33% | 63.05% | 11804.29% | Upgrade
|
| Other Receivables | 1 | 0.8 | 0.5 | - | - | 0.04 | Upgrade
|
| Receivables | 1 | 0.8 | 0.5 | - | - | 0.04 | Upgrade
|
| Prepaid Expenses | 9.65 | 8.53 | 10.07 | 10.5 | 7 | 6.43 | Upgrade
|
| Restricted Cash | 0.19 | 0.59 | 0.69 | 0.7 | - | - | Upgrade
|
| Total Current Assets | 229.63 | 347.6 | 438.42 | 240.75 | 373.27 | 231.1 | Upgrade
|
| Property, Plant & Equipment | 73.74 | 74.01 | 73.08 | 56.34 | 34.81 | 18.02 | Upgrade
|
| Long-Term Investments | - | - | - | - | - | 11.97 | Upgrade
|
| Other Long-Term Assets | 1.14 | 1.81 | 2 | 1.04 | 0.55 | 0.26 | Upgrade
|
| Total Assets | 304.51 | 423.41 | 513.5 | 298.13 | 408.63 | 261.35 | Upgrade
|
| Accounts Payable | 3.55 | 1.33 | 2.51 | 5.58 | 7.92 | 3.09 | Upgrade
|
| Accrued Expenses | 31.07 | 31.54 | 33.62 | 18.88 | 6.65 | 3.31 | Upgrade
|
| Current Portion of Leases | 6.7 | 5.83 | 5.82 | 3.32 | 2.67 | 2.48 | Upgrade
|
| Current Unearned Revenue | 2.65 | 3.78 | 2.74 | - | - | - | Upgrade
|
| Total Current Liabilities | 43.96 | 42.48 | 44.69 | 27.78 | 17.24 | 8.88 | Upgrade
|
| Long-Term Leases | 39.16 | 34.67 | 35.36 | 25.44 | 9.58 | 12.24 | Upgrade
|
| Long-Term Unearned Revenue | 141.88 | 143.02 | 146.2 | - | - | - | Upgrade
|
| Other Long-Term Liabilities | 0.55 | - | - | - | - | - | Upgrade
|
| Total Liabilities | 225.56 | 220.18 | 226.24 | 53.22 | 26.82 | 21.12 | Upgrade
|
| Common Stock | 0.59 | 0.59 | 0.43 | 0.33 | 0.32 | 0.3 | Upgrade
|
| Additional Paid-In Capital | 1,058 | 1,024 | 862.36 | 598.37 | 570.03 | 347.09 | Upgrade
|
| Retained Earnings | -980.39 | -821.24 | -574.83 | -353.72 | -188.56 | -107.21 | Upgrade
|
| Comprehensive Income & Other | 0.42 | 0.15 | -0.7 | -0.07 | 0.03 | 0.04 | Upgrade
|
| Total Common Equity | 78.95 | 203.23 | 287.26 | 244.91 | 381.82 | 240.23 | Upgrade
|
| Shareholders' Equity | 78.95 | 203.23 | 287.26 | 244.91 | 381.82 | 240.23 | Upgrade
|
| Total Liabilities & Equity | 304.51 | 423.41 | 513.5 | 298.13 | 408.63 | 261.35 | Upgrade
|
| Total Debt | 45.86 | 40.51 | 41.17 | 28.76 | 12.24 | 14.73 | Upgrade
|
| Net Cash (Debt) | 172.93 | 297.17 | 385.99 | 200.78 | 354.03 | 209.91 | Upgrade
|
| Net Cash Growth | -49.99% | -23.01% | 92.24% | -43.29% | 68.66% | - | Upgrade
|
| Net Cash Per Share | 2.87 | 5.68 | 9.29 | 6.00 | 11.51 | 23.33 | Upgrade
|
| Filing Date Shares Outstanding | 59.46 | 58.79 | 43.18 | 32.51 | 32.01 | 30.56 | Upgrade
|
| Total Common Shares Outstanding | 59.45 | 58.68 | 43.08 | 32.5 | 31.97 | 30.49 | Upgrade
|
| Working Capital | 185.67 | 305.12 | 393.74 | 212.97 | 356.03 | 222.23 | Upgrade
|
| Book Value Per Share | 1.33 | 3.46 | 6.67 | 7.54 | 11.94 | 7.88 | Upgrade
|
| Tangible Book Value | 78.95 | 203.23 | 287.26 | 244.91 | 381.82 | 240.23 | Upgrade
|
| Tangible Book Value Per Share | 1.33 | 3.46 | 6.67 | 7.54 | 11.94 | 7.88 | Upgrade
|
| Machinery | - | 35.12 | 26.26 | 18.35 | 7.34 | 3.95 | Upgrade
|
| Construction In Progress | - | 5.8 | 5.11 | 2.53 | 17.93 | 1.12 | Upgrade
|
| Leasehold Improvements | - | 17.91 | 14.43 | 14.17 | 0.25 | 0.08 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.